Navigation Links
Nano Mask Enters Into Four-Year Distribution Agreement With Saudi Medical Products Distributor
Date:8/25/2011

FISHKILL, N.Y., Aug. 25, 2011 /PRNewswire/ -- Nano Mask, Inc. (NMI) (Pink Sheets: NANM), a healthcare product development and distribution company focused on emergency and critical care as well as infection control markets, has announced that it has entered into a distribution agreement with a Saudi Arabia-based medical products distributor which will represent NMI's product line on an exclusive basis to: The Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Egypt, Morocco, Oman, Algeria, Qatar, Jordan, Bahrain, Sudan, Yemen Lebanon, Yemen and Tunisia.

In exchange for four years of exclusive rights to distribute NMI's product line in the Territory, the Saudi Arabian medical products distributor, having already delivered to date over $90,000.00 in orders, has agreed to order a minimum of $ 2,300,000 over the next four years. The products that will be marketed and sold in the Territory are NMI's emergency life support and respiratory products (utilizing the company's industry leading patented 2H Filtration Technology), antimicrobial hospital barrier products and NMI's proprietary line of bacteria free enzymatic medical detergents specially formulated for instrument reprocessing.

"This agreement, which covers 15 Middle Eastern countries, represents the first of what we hope will be many international distribution agreements for our products," said Eddie Suydam, President and CEO, NMI.

Mr. Suydam added, "We are currently in negotiations with other medical products distributors, both domestic and international, to sell our products and expect that we will begin to see some meaningful sales from our marketing efforts in the near future."

About Nano Mask, Inc.

NMI is the inventor of 2H Technology, an advanced dual filtration system which is designed to remove infectious bacteria and virus from airflow systems at extremely high levels of efficiency. In addition to the company's advanced filtration materials and products, NMI also markets a line of innovative infection control products which range from proprietary enzymatic instrument reprocessing solutions to innovative antimicrobial textiles in the United States and internationally.

Forward-looking Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect the planned timeline for initiating actual sales of the product. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.

Contact:
For further information:
Ed Suydam  
(914) 760-7857  
eds@nmihealth.com


'/>"/>
SOURCE Nano Mask, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
(Date:4/27/2016)... April 27, 2016  Bayer Animal Health today ... from the University of Florida College of Veterinary ... Excellence in Communication Award (BECA). Brittany was selected ... awarded a total of $70,000 in scholarship funds ... years, Bayer has provided a total of $232,500 ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive ... to announce one of their physicians has been invited to be a featured speaker ... Family Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader in ... by Eastside Partners, with participation from existing investor Martin Ventures. The funds ... its technology and product roadmap. , “Jvion is experiencing significant growth ...
(Date:4/29/2016)... ... 29, 2016 , ... Nike Softball Camp at the College of Brockport in ... for girls aged 10-18. All facets of the game will be covered; hitting, fielding, ... Complex, one of the finest softball facilities in the region. The outstanding professional college ...
Breaking Medicine News(10 mins):